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Abstract:  Non-cirrhotic portal hypertension (NCPH) has been recently reported as a liver disease in Human 
Immunodeficiency Virus (HIV)-infected patients under antiretroviral therapy (ART). Combination of non-exclusive 
mechanisms has been described: primary endothelial damage of terminal portal veins induced by HIV or immunologic 
disorders, mitochondrial toxicity by didanosine and prothrombotic state. It is characterized by heterogeneous liver 
histological findings, frequently identified as nodular regenerative hyperplasia and clinical manifestations of portal 
hypertension with well-preserved liver function. We describe herein two HIV-infected patients with clinical picture 
suggestive of NCPH. Besides the case reports, we briefly address questions to apply to patient care in clinical practice. 
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INTRODUCTION 
  Non-cirrhotic portal hypertension (NCPH) is an 
emerging clinical condition reported in Human 
Immunodeficiency Virus (HIV)- infected patients controlled 
with antiretroviral therapy (ART), consisting of intrahepatic 
portal hypertension, in the absence of cirrhosis and other 
known etiologies of liver disease. 
  A multifactorial mechanism has been proposed to explain 
the pathogenesis of NCPH. 
  Pre-hepatic portal venulopathy [1], through primary 
endothelial cell injury by HIV or didanosine [2] (other 
adenosine analog, like azathioprine [3], have been reported 
to induce similar lesion). This damage might lead to 
obliteration of the small portal veins, ischemia of the 
supplied acini and regenerative hyperplasia of the 
remainders, in order to maintain liver cell mass. 
 Prothrombotic  state, by HIV as a direct cause or through 
anti protein S antibodies [4], leading to protein S deficiency, 
results in an obliteration of the small portal venules and liver 
regenerative hyperplasia. 
  Therefore, didanosine and protein S low levels might be 
revealed as cofactors in pathogenesis of NCPH. 
  Pathologic hallmark would be a continuum and 
heterogeneous spectrum: subtle features which may be 
missed, nodular regenerative hyperplasia (also described in 
the setting of immunologic, malignant, hematologic and 
gastrointestinal infectious disorders), hepatoportal sclerosis 
[5] with the absence of advanced hepatic fibrosis or 
microvesicular steatosis (which could reflect mitochondrial 
damage induced by nucleoside reverse transcriptase   
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inhibitors, like didanosine [6]). Presinusoidal portal 
hypertension appears as the hemodynamic profile of NCPH, 
showing normal or mildly elevated (<10 mmHg) hepatic 
venous pressure gradient [7]. 
  Didanosine has been postulated as an independent predictor 
of developing NCPH [6, 8], through cumulative dosing or 
idiosyncratic mechanisms [9]. Taking in account the last 
consideration, polymorphisms at genes involved in the 
metabolism of didanosine might predispose to veno-occlusive 
liver disease. In addition, removal of didanosine has appeared to 
be associated with clinical and laboratory improvements. 
  It is noteworthy that in guidelines for the use of 
antiretroviral agents in HIV-1-infected adults and adole-
scents (DHHS, December 1, 2009) [10], potential association 
with NCPH has been reported as an adverse event. 
  On the other hand, portal thrombosis has been frequently 
described at follow-up of NCPH. A `two hit´ model has been 
proposed [9]: portal endothelial damage, associated with 
long-term exposure of didanosine and repeated episodes of 
pylephlebitis, through disruption of intestinal barrier by HIV 
infection and anal sex practices in men who have sex with 
men (MSM), leading to reduced portal flow with added 
prothrombotic state, which might lead to develop portal 
thrombosis. 
  Despite the development of portal hypertension, liver 
synthetic function tests (prothrombin time, albumin) may be 
relatively well preserved, while progressive cholestasis and 
elevated serum aminotransferases appear on evolution. 
Decompensated liver pictures (ascites, bleeding due to 
esophageal varices) are frequent at the onset of clinical 
NCPH, through portal hypertension. In addition, portal 
thrombosis could be both the cause and consequence of liver 
decompensation. 
  We have identified two patients at our Spanish centre 
who fulfil the criteria for NCPH and we would like to 
describe them. 60    The Open AIDS Journal, 2011, Volume 5  Díaz et al. 
CASE REPORTS 
Case 1 
  A 58 year-old Caucasian man, a teacher in a primary 
school, was admitted to the hospital in February 2000, for 
evaluation of an esophageal ulcer and genital warts. HIV 
infection was diagnosed and antiretroviral therapy (ART) 
with zidovudine, lamivudine and nelfinavir was started. In 
January 2003, ART was changed to didanosine, stavudine 
and efavirenz, due to virological failure. Cholestasis and 
elevated serum aminotransferases appeared in blood test and 
infection with hepatitis B and hepatitis C virus was ruled out. 
A liver biopsy was performed in January 2004 and histology 
was unremarkable. In March 2004, ART was changed again 
to atazanavir/ritonavir booster and tenofovir, due to 
lipoatrophy linked to stavudine. Didanosine was continued. 
In September 2004, tenofovir was switched to backbone of 
zidovudine/lamivudine, due to hypophosphatemia and 
proteinuria associated with tenofovir. In December 2004, 
abdominal computed tomographic scan showed ascites and 
portal hypertension. In February 2005, an upper endoscopy 
revealed grade 3-4 distal esophageal varices and beta-
blockers for primary prophylaxis of variceal bleeding were 
prescribed. Iron deficiency anemia appeared at follow-up 
and transfusion of several packed red cells was required. In 
June 2008, zidovudine was changed to abacavir to reduce 
hematologic toxicity. In September 2009 (under ART with 
abacavir, lamivudine, atazanavir/ritonavir and didanosine), 
the patient was admitted to the hospital because of bleeding 
from esophageal varices and he had to be transferred to 
intensive care unit to receive mechanical ventilation, 
hemodynamic support, pharmacotherapy (terlipressin) and 
banding ligation of esophageal varices. One month later, the 
patient was readmitted to the hospital because of new 
bleeding from esophageal varices, requiring banding ligation 
again. He was transferred to another hospital, where a 
transjugular intrahepatic portal systemic shunt (TIPS) was 
placed to connect the portal to right suprahepatic vein. Left 
branch portal vein thrombosis, mild splenomegaly and 
chronic liver disease were demonstrated by abdominal 
Doppler ultrasound. At discharge from hospital, didanosine 
was removed and the remainder antiretroviral scheme was 
continued (abacavir, lamivudine and atazanavir/ritonavir). 
Two months later, CD4 cell count was 131/mcl (12%) and 
viral load was below 50 copies/ml. Nowadays, the patient 
has a satisfactory general condition and he has been 
considered for liver transplantation [11]. 
Case 2 
  A 41-year-old Caucasian woman was admitted to the 
hospital in July 1998, because of Pneumocystis jiroveci 
pneumonia, oral candidiasis and pulmonary tuberculosis. 
HIV infection was diagnosed and ART with didanosine, 
stavudine and nevirapine was started. Two years later, 
progressive cholestasis appeared in blood test and infection 
with hepatitis B and hepatitis C virus was ruled out. In June 
2003, the patient was admitted to the hospital because of 
bleeding from grade 2-3 esophageal varices. Sclerosis and 
banding ligation were performed, but main portal vein stent 
placement was required to connect the portal vein to inferior 
vena cava. Abdominal Doppler ultrasound showed massive 
ascites, left branch portal and splenoportal vein nonocclusive 
thrombosis, as well as chronic liver disease. Autoimmunity 
parameters disclosed slightly positive anti-smooth muscle 
and negative antinuclear, antimitochondrial and anti-liver 
kidney microsomal antibodies. She was evaluated for 
hypercoagulable state and was found to have low 
antithrombin III values at the time of hematemesis. Sixteen 
months later, low protein C and S values were found. A liver 
biopsy showed patchy sinusoidal dilatation and congestion, 
collapsed liver cell plates and nodular areas without 
extensive fibrosis, all of these findings being suggestive of 
nodular regenerative hyperplasia. In April 2005, ART was 
changed to abacavir/lamivudine and lopinavir/ritonavir 
booster (didanosine was removed), due to virological failure 
and according to resistance test. An abdominal ultrasound 
performed in March 2009 showed patent shunt. Eight 
months later, CD4 cell count was 1005/mcl (36 %), viral 
load was below 50 copies/ml, and the patient had a 
satisfactory general condition. 
DISCUSSION 
  Both patients had had heterosexual relationships as mode 
of HIV infection (nevertheless, in most of previous case 
series, predominance of MSM has been reported [8]). No 
liver enzyme elevations were noted before initiating ART 
and progressive cholestasis appeared after it (ART scheme 
including didanosine). They did not relate alcohol or other 
illicit drugs consumption and hepatitis B and C virus 
serology was negative. An evaluation of autoimmune 
parameters in second case did not reveal remarkable results. 
At the onset they presented with life-threatening upper 
gastrointestinal bleeding, under didanosine exposition of 6 
years in first case (ascites and grade 3-4 esophageal varices 
had been noted four years before) and 5 years in second one. 
TIPS was required in first case and portal stent in second 
one. Left branch portal vein thrombosis was reported in both 
cases. Hypercoagulable state was not evaluated in first case, 
but protein C and S low levels were found in second patient 
(two determinations more than one year apart). Despite this 
finding, anticoagulation was not initiated. Liver biopsy was 
unremarkable in first case and findings compatible with 
nodular regenerative hyperplasia were disclosed in second 
one. Didanosine was removed from ART schema in both 
patients. 
  Questions and remarks arise from clinical practice: 
-  Referring to data regarding prothrombotic 
abnormalities in HIV-infected patients [12]: Should 
patients with HIV and non-cirrhotic portal 
hypertension be evaluated for hypercoagulable state? 
-  Risks linked to anticoagulation in this setting (i.e., 
bleeding from esophageal varices), above all if portal 
thrombosis appears, should be assessed. 
-  Removing didanosine from ART scheme should be 
considered. In addition, clinicians should be aware of 
novel long-term toxicities attributable to ART. 
-  High index of suspicion of NCPH, close monitoring 
of patent portal vein and risk of variceal hemorrhage, 
must be warranted. 
-  Which is the role of noninvasive methods (i.e., 
transient elastography or Fibro-test) for identification 
and monitoring of patients with NCPH in future? Non-Cirrhotic Portal Hypertension in Human Immunodeficiency Virus-Infected Patients  The Open AIDS Journal, 2011, Volume 5    61 
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